Toward individualized breast cancer therapy: Translating biological concepts to the bedside

Oncologist

Volumn 17, Issue 4, 2012, Pages 577-584

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; DEATH; GENE EXPRESSION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM RECURRENCE, LOCAL;

EID: 84860195931     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0032     Document Type: Review

References (50)

1. HouseofNames.com. Pinedo Family Crest and Name History. Available at http://www.houseofnames.com/pinedo-family-crest, accessed September 28, 2011.
2. Wikipedia. Cartularios de Valpuesta. Available at http://en.wikipedia.org/wiki/Cartularios_de_Valpuesta, accessed September 28, 2011.
3. Available at http://www.google.com/search?q=famous+Pinedos&rls=com.microsoft:&z.ast;&ie=UTF-8&oe=UTF-8&startIndex=&startPage=1, accessed September 28, 2011.
4. Swenerton KD, Legha SS, Smith T et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979;39: 1552-1562.
5. Halsted WS. I. The Results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 1894;20:497-555.
6. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 1896;ii:162-165.
7. Fisher ER, Fisher B. Relationship of pathologic and some clinical discriminants to the spread of breast cancer. Int J Radiat Oncol Phys 1977;2:747-750.
8. Hortobagyi GN, Smith TL, Legha SS et al Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983;1:776-786.
9. Fisher ER, Anderson S, Redmond C et al. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71: 2507-2514.
10. Haybittle JL, Blamey RW, Elston CW et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-366.
11. Ravdin PM, Clark GM, Hilsenbeck SG, et al. A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat 1992;21:47-53.
12. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-2725.
13. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
14. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351: 2817-2826.
15. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984.
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
17. Clarke M, Collins R, Darby S et al.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366: 2087-2106.
18. Ross MB, Buzdar AU, Smith TL et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 1985;55:341-346.
19. Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004;100: 44-52.
20. Peto R, Boreham J, Clarke M et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
21. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
22. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. Cancer J 2007;13:148-155.
23. Tao Y, Klause A, Vickers A et al. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 2005;95:91-95.
24. Tang G, Cuzick J, Costantino JP et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 2011;29:4365-4372.
25. Tang G, Shak S, Paik S et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133-142.
26. Buyse M, Loi S, van't Veer L et al.; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with nodenegative breast cancer. J Natl Cancer Inst 2006;98: 1183-1192.
27. Sparano JA. TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7:347-350.
28. Rutgers E, Piccart-Gebhart MJ, Bogaerts J et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. Eur J Cancer 2011;47:2742-2749.
29. Gonzalez-Angulo AM, Barlow WE, Gralow JR et al. Arandomized phase III clinical trial of standard adjuvant endocrine therapy ± chemotherapy in patients (pts) with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less: SWOG S1007 [abstract OT1-03-01]. Cancer Res 2011; 71(24 suppl):607s.
30. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-247.
31. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: Importance of heterogeneity. Nat Rev Clin Oncol 2010;7:139-147.
32. Osborne CK, Neven P, Dirix LY et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized phase II study. Clin Cancer Res 2011;17:1147-1159.
33. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
34. Cristofanilli M, Valero V, Mangalik A et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010;16: 1904-1914.
35. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAn-DEM study. J Clin Oncol 2009;27:5529-5537.
36. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011;10:1093-1101.
37. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011; 366:520-529.
38. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
39. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 2010;28: 92-98.
40. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009;14:320-368.
41. Yin W, Jiang Y, Shen Z et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One 2011;6:e21030.
42. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685-5692.
43. Bailey TA, Luan H, Clubb RJ et al. Mechanisms of trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog 2011;10:28.
44. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
45. Baselga J, Cortés J, Kim SB et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
46. Morrow PK, Wulf GM, Ensor J et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011;29: 3126-3132.
47. Carey L, Winer E, Viale G et al. Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683-692.
48. Pusztai L, Ayers M, Symmans FW et al. Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 2003; 21(23 suppl):237.
49. Iwamoto T, Lee JS, Bianchini G et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011;130:155-164.
50. Javle M, Curtin NJ. The potential for poly-(ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011;3:257-267.